Background:
Interstitial lung disease (ILD) is a severe extra-articular complication of Rheumatoid Arthritis (RA). The decrease in DLCO diffusion is the most sensitive value for the detection of ILD, DLCO is also a prognostic factor. Objectives: To study the prevalence of subclinical lung involvement in early RA. Methods: Cross-sectional study of lung involvement in early RA. The following criteria were used: A) RA according to the EULAR-2010 criteria. B) Early RA if evolution from the onset of symptoms to the diagnosis of RA was less than one year. C) Lung affectation if DLCO diffusion was lower than 80%. In each patient we evaluate: a) presence of dyspnea according to MMRC (Modified British Medical Research Council) scale; B) Respiratory function tests (FVC, FEV1, FEV1/FVC; C) DLCO; classifying the degree in: i) normal>80% (mild decrease 80-60%); ii) Moderate decrease (60-40%) and iii) Severe reduction (<40%); D) Chest x-ray: assessed by radiologist. E) Joint activity of RA (DAS28), F) CRP and ESR. G) RF, CCPA, H) Presence of atheroma plaque on carotid ultrasound. Quantitative variables were expressed as mean±SD or median [IQR] and were compared with the Student t or Mann Whitney U test, respectively. Dichotomous variables were expressed as percentages and compared using the chi-square test. Statistical analysis was performed with the SPSS 15.0 program. Results: 20 patients (15 women/5 men) with early RA were studied; mean age of 54.1±13.4 years. Some patients were using disease-modifying antirheumatic drugs (DMARDs) prior to performing respiratory function tests (PFR): methotrexate (7) 3 of them with less than 14 days of treatment, hydroxychloroquine (4), sulfasalazine (1). The table shows the main characteristics of patients according to pressence of lung disease. We observed a decrease in DLCO in 15/20 patients (75%) who were mild (DLCO <80%) in 4 (27%); Moderate (DLCO <60%) in 9 (60%) and severe (DLCO <40%) in 2 (13%). Chest x-ray showed these alterations in 3 patients: signs of air trapping, laminar atelectasis and scarring tracts. There were no alterations in FVC in any patient. Background: The treatment of Rheumatoid Arthritis (RA) has been transformed in the last decade with the introduction of biologic therapy. Nevertheless, a substantial proportion of patients (pts) are found to be primary or secondary nonresponders and will receive several biologics during the course of the disease. Evidence is lacking on the characterization of patients failing several agents and those who have adequate clinical response to their first biological treatment. Objectives: To compare demographic, clinical and analytical characteristics in a cohort of RA pts who have failed treatment with at least two biological agents ("switchers") and another cohort of RA patients showing a sustained clinical good response to their first therapy ("maintainers"). As a secondary objective, reasons for therapy discontinuation were also evaluated. Methods: A total of 186 patients under biological therapy of the RA-PAZ cohort were included in this observational study. In this cohort, 63 pts were switchers and 123, maintainers. Baseline demographic data and clinical disease activity (DAS 28 -ESR), clinical improvement (delta-DAS 28) and serological data (CRP and ESR) were evaluated at baseline and sixth months after starting the first biological treatment.Serum anti-drug antibodies (ADA) were measured by bridging ELISA at the last visit available during the follow-up period under the first treatment. Reasons for discontinuation of the first therapy and the number of biologic treatments received during the course of the disease were also evaluated. Results: Demographic and clinical characteristics of both groups are shown in Table 1 .Mean Age (49,96±10,82 vs 53,77±12,91,p=0,046) and disease duration (6,79±6,19 vs 9,97±8,56,p=0,001) prior to biologic therapy initiation were lower in the switchers.Furthermore, a higher proportion of switchers had extraarticular manifestations in comparison to the maintainers (18/63 (28,6%) vs 16/121 (13,2%),p=0,016). Clinical activity at baseline (DAS28: 5,74±1,26 vs 5,01±1,14,p=0,01) and after 6 months of starting the first biological therapy (DAS28: 4,45±1,6 vs 3,22±1,1,p=0,001) were statistically significant higher in the switchers. At the last visit under the first biologic, there were also more ADA-positive pts in the switchers (6/25 (24%) vs 1/73 (1,4%), p=0,01).Moreover, duration under biologic treatment was higher in this group. In terms of the reason for discontinuation of the first biologic, 22,2% of pts showed primary lack of efficacy;38,1%, secondary loss of efficacy; 33,3%, adverse effects;4,8%interrupted because of other reasons and 1,6% because of remission. There was no association between reasons for discontinuation of the first therapy because of primary or secondary failure and adverse effects (3,4±0,9 vs 3,75±1,11vs 3,86±1,3, p=0,6) with the number of treatments received. Conclusions: In our biologic therapy RA-PAZ cohort, we found a subgroup of younger pts, with a more systemic phenotype of the disease and a higher disease activity,who required a prompter biological therapy initiation. This subgroup of pts is more susceptible to biological treatment failures. The development of ADA after the first biological agent was also associated with the need to use more biologics. Background: Optimizing treatment in early rheumatoid arthritis (ERA) improves clinical outcomes. Developing approaches that would allow for accurate outcome predictions would be useful. We examined the possibility of employing SOMAscan to identify biomarkers that predict treatment response. Objectives: To define methotrexate (MTX) 6 month treatment associated response protein changes using SOMAscan. Methods: Sera from 14 Disease Modifying Antirheumatic Drug (DMARD) naive ERA patients at baseline (PRE) and after six months of MTX (POST) were analyzed using SOMAscan, an aptamer based assay that offers simultaneous relative quantitation of 1310 proteins. RA activity was measured by DAS28ESR3var abbrev DAS3; RF and ACPA were measured at baseline. SOMAmer intensity data was log2 transformed and differences (D=POST-PRE) clustered using undirected hierarchical self-organization. Kolmogorov-Smirnov differential analysis determined SOMAmers contributing to these populations at p<0.05. Potential processes associated with these SOMAmer regulation groups were identified using an in-house biological enrichment tool. The potential for SOMAmers to predict treatment response was also explored; for this we defined a fractional clinical response metric dDAS3= (DAS3_POST-DAS3_PRE)/DAS3_PRE. We then selected a population of proteins (n=3 to avoid over-fitting) with PRE expression levels best correlating to dDAS3. These three PRE expression values formed a weighted average, with weighting coefficients optimized by a simple Monte-Carlo method. We included this weighted average with clinical variables in logistic regression models, where 6 month DAS3 was the dependent variable. Results: Clustering gave two populations of 6 and 8 patients (POP0, POP1) with mean delta DAS3 values of -1.71 and -0.46 respectively. In POP0 compared to POP1, 113 proteins were upregulated and 121 proteins were downregulated. The upregulated proteins were involved in VEGF signalling and platelet activation. The downregulated proteins were involved in regulation of immune response, cellular response to TNF and cytokine -cytokine receptor interactions. The fractional change dDAS3 correlated well with the treatment response panel (R 2 =0.8645; p=6.8e-5), with the caution that expression values of the 3 best-correlating proteins exhibited low coefficients of variation (<0.1). However, these proteins did reflect RA responses or inflammation. This weighted sum was also independently associated with treatment response in regression models including baseline DAS3 (or components) and RF/ACPA. Conclusions: This pilot study suggests that high content proteomic approaches such as SOMAscan may be useful for developing prediction tools of patient responses to treatment. Extension of this work into a larger patient population is ongoing. 
